Medical Biotechnology and Alzheimer’s disease

Presently, medical biotechnology is ushering in newfound optimism for the management of Alzheimer's disease. An illustration of this progress can be found in on-going clinical trials, representing a significant breakthrough as the initial drug aimed at impeding or potentially arresting the advancement of Alzheimer's disease. In the field of structural techniques, both magnetic resonance imaging (MRI) and computed tomography (CT) are instrumental in offering insights. Meanwhile, functional imaging unveils the efficacy of cells in various brain regions by demonstrating the active utilization of sugar or oxygen.

    Related Conference of Medical Biotechnology and Alzheimer’s disease

    July 20-21, 2026

    37th World Congress on Neurology and Neuroscience

    Amsterdam, Netherlands
    July 23-24, 2026

    14th International Conference on Cannabis & Medicinal Research

    Amsterdam, Netherlands
    September 18-19, 2026

    21st Annual Congress on Neuroscience

    Dubai, UAE
    November 16-17, 2026

    8th World Brain Congress

    Tokyo, Japan
    November 23-24, 2026

    16th Global Alzheimers Summit

    Paris, France
    November 24-25, 2026

    38th World Conference on Neurology

    Rome, Italy
    December 16-17, 2026

    12th International Conference on Brain Injury & Neuro Surgeons

    Amsterdam, Netherlands
    December 21-22, 2026

    6th International Conference on Child Neurology

    Paris, France
    December 28-29, 2026

    39th European Neurology Congress

    Amsterdam, Netherlands
    December 28-29, 2026

    18th Global Neurologists Meeting on Neurology and Neurosurgery

    Amsterdam, Netherlands
    March 22-23, 2027

    8th International Conference on Neurologists

    Singapore City, Singapore

    Medical Biotechnology and Alzheimer’s disease Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in